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Introduction
Pyomyositis is a rare infectious disease that is
difficult to diagnose. It is a spontaneous purulent
infection of skeletal muscle, first described by
Scriba in 1885,1 who reported 4 cases. It is rare in
temperate climates. Grose2 reported an incidence
rate of 1 per 3,000 pediatric admissions in southern
Texas. The pathogenesis of pyomyositis remains
unknown and transient bacteremia is suspected.3 Its
clinical course is subacute and is often not noted until
the secondary stage, leading to delays in effective
treatment.4–9
Pyomyositis occurs in children receiving
induction therapy for acute lymphoblastic leukemia
(ALL). A search of the MEDLINE database found
4 cases. In 1979, Blatt et al9 first described it in
2 children with ALL, occurring a few weeks after
the initiation of induction therapy. In 1996, Corden
and Morgan10 also presented 2 cases suffering from
pyomyositis shortly after induction therapy.  In 2004
we also noted a patient with ALL who developed
pyomyositis during induction chemotherapy. In this
report, we describe our case and the 4 cases recorded
in MEDLINE.
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Case Report
A 10-year-old Taiwanese girl was transferred to our
hospital on May 20, 2004, because of severe anemia.
On physical examination, she was weak and pale. Her
abdomen was soft and flat without palpable liver or
spleen. A 1 = 1-cm lymph node was noted over the
right retro-sternocleidomastoid area. There were some
ecchymoses over her left arm. The hemogram showed:
white blood cells (WBC), 5000/+L; hemoglobin,
4.6 g/dL; MCV, 90/fL; and platelet counts, 7,000/+L.
Blood chemistry revealed: aspartate aminotransferase
(AST) 86 U/L (reference, 5~45 U/L); alanine
aminotransferase (ALT), 47 U/L (reference, 0~40
U/L); alkaline phosphatase, 169 U/L (reference,
10~100 U/L); lactate dehydrogenase, 404 U/L
(reference, 95~213 U/L); and uric acid, 5.1 mg/dL
(reference, 1.8~7.2 mg/dL). Acute leukemia was
suspected and we performed bone marrow aspiration.
The smears showed hypocellularity almost replaced by
homogeneous high nuclear-to-cytoplasmic ratio blasts.
The trilineage precursors depressed markedly. The cell
marker analysis revealed: CD19, 89.9%; CD10, 73.7%;
CD20, 7.8%; CD2, 4%; CD3, 4.6%; CD7, 3.5%. Acute
precursor B-lymphoblastic leukemia was diagnosed.
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induction chemotherapy TPOG regimen with vincristine
(1.5 mg/m2), epirubicin (20 mg/m2), and prednisolone
(40 mg/m2) began. Mild nausea and vomiting were
noticed initially. One episode of low-grade fever, up to
38.2$C, was noted after 5 days of chemotherapy but it
subsided spontaneously. The chemotherapy was
continued without delay. However, the patient suffered
from left chest wall pain on the 6th day of chemotherapy.
There was no local sign of erythema, tenderness, or
swelling and her WBC counts were 600/+L. Vincristine
and epirubicin continued on the 8th day under the
probability of neuropathic pain of vincristine. However,
right thigh pain, followed by bilateral lower leg pain
occurred on the 12th day. There was still no local sign
of erythema, tenderness, or induration over these painful
areas, including the initial lesion of the left chest wall.
Fever developed on the 14th day of chemotherapy,
with local tenderness, swelling, and local heat. Empiric
antibiotics including vancomycin and ceftazidime were
administered and the fever subsided on the 5th day.
However, the initially painful lesions were still swelling.
Soft-tissue ultrasonography revealed an accumulation
of fluid in her left chest wall and right thigh (Figures
1 and 2). Needle aspiration yielded drainage of 1–2
mL pus. Meanwhile, the blood culture before antibiotic
prescription yielded methicillin-sensitive Staphylococcus
aureus. In the following days, a pigtail was inserted in
her right thigh because of increased fluid accumulation.
The abscess was drained for 11 days, producing a total
of 183.5 mL pus fluid. Gram stain and culture revealed
no growth. Vancomycin was continued for 4 weeks
before shifting to the oral form of oxacillin for 2 weeks.
She received regular follow-up at our hospital and
continued the full course of chemotherapy, including
early intensification and maintenance. There was no
recurrent event of pyomyositis (course charted in
Figure 3).
Discussion
Pyomyositis refers to spontaneous abscess of skeletal
muscle. It is predominant in tropical areas, and less
common in temperate climates where it is responsible
for 1 in 3,000 pediatric admissions.2 It can be seen in
all age groups and is most common in the first and
second decades of life.11 In acute leukemia, ALL is
prevalent in this age group, but pyomyositis remains a
very rare complication in children under induction
chemotherapy for ALL.10 Four boys and 1 girl, aged
between 9 and 19 years, have been reported as suffering
from this complication in the literature. The clinical
presentations are listed in Table 1.
It is difficult to diagnose pyomyositis in children
with ALL for the following reasons. First, neuropathic
pain is a common complication under vinca alkaloid
chemotherapy, including vincristine.12,13 Initial
symptoms of pyomyositis can be mistaken as the side
effects of induction therapy. Second, early examination
rarely yields a specific finding to confirm pyomyositis.
All 5 cases reported showed a similar clinical course
(Table 1). Local pain began after 1–3 weeks of induction
therapy. The prescription in common was vincristine,
a drug necessary for ALL induction therapy that
unfortunately often causes neuropathic or limb
pain.12,13 Local pain can be managed by supportive care,
but it might also be a common sign of pyomyositis.8
Figure 2. A 15 = 3.5 = 2.5-cm heterogeneous lesion with
echogenic floating material is noted at the antero-lateral aspect
of the right thigh on ultrasonography.
Figure 1. A 1.5 = 0.45-cm hypoechoic lesion is noted at the left
chest wall on ultrasonography.
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Because the clinical presentation of pyomyositis is
rare and vague, the chances of it being listed in the
initial diagnosis are low, especially due to the vincristine-
induced pain effect. The delay in diagnosis may
result in serious complications, such as compartment
syndrome, extension into and destruction of an adjacent
joint, sepsis, abscess formation on another site, and,
occasionally, death. The long-term sequelae of
pyomyositis include osteomyelitis, muscle-scarring,
residual weakness, and functional impairment.11
Although none of the 5 cases mentioned earlier died,
pyomyositis may affect the course of chemotherapy for
ALL, especially when treatment is delayed as a result of
the above-mentioned complications.
Pyomyositis requires many investigations. However,
the data collected are often more helpful for the
treatment course than for the diagnosis. There is
usually no specific finding in the hemogram and
Figure 3. The case patient's hospital course.
Table 1. Clinical presentation in 5 cases with pyomyositis during induction chemotherapy for acute lymphoblastic leukemia*
Case from Age (yr) Time after Initial Lesion Initial Initial
reference /sex induction symptom site sign temperature ($C) WBC
Blatt et al9 19/M 3 weeks R calf Pain Tender (+) 38.5 1,000
R elbow Rash
Blatt et al9 12/M 1 week R calf Pain Erythema 38.3 400
L thigh Rash
Corden and Morgan10 9/M 3 weeks Bilateral thigh Pain Weak 37.8 13,700
Corden and Morgan10 10/M 18 days L leg Pain Limping Low-grade fever 10,700
Our case 10/F 6 days L chest wall Pain 38.2 600
WBC = white blood cell; M = male; F = female; R = right; L = left.
*Induction drugs used in our case were vincristine, epirubicin, and prednisolone. Those used in the other cases were vincristine, daunorubicin,
prednisolone, and L-asparaginase
Symptoms
Treatment
6th day: chest pain, but no
finding on physical exam
20th day: abscess noted by echo, and on needle
aspiration. Blood culture yielded S. aureus
5th day: fever, subsided
spontaneously
12th day: left thigh pain, but no local sign
14th~19th days: fever for 5 days
8th day: chemotherapy
35th day: on pigtail, keep 11 days
14th day: start antibiotics, keep for 6 weeks
0 day: ALL induction start
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blood chemistry at the beginning. Leukocytosis,
elevated C-reactive protein, and elevated erythrocyte
sedimentation rates may be seen at the suppurative
stage if patients are not at the nadir stage. Plain
films are not helpful in diagnosis.14 Ultrasound could
be used to detect fluid collection, especially at
the suppurative stage, but it is far more difficult in
the early diagnosis if there is no fluid formation.
Subtle findings, such as altered echogenicity, may
result in it being easily overlooked.14 It is important to
determine the causative agent, under ultrasound-
guided aspiration.
S. aureus is the most common infecting organism
in pyomyositis (> 90%) and streptococcal infection is
the second most common organism.3 The organism
cultured in these 5 cases was S. aureus (Table 2).
Therefore, initial empirical antibiotic therapy should
cover Staphylococcus,2–4,8,10,11 and should begin as early
as possible to avoid massive pus formation. Some
healthy children suffering from pyomyositis are cured
by antibiotic therapy only.8 However, in addition to
antibiotic therapy, children with ALL often need
surgical drainage because of enlarged abscess
accumulation, as in the 5 cases described herein. One
case experienced redebridement due to reaccumulation
of pus fluid.15 Different from the other 4 cases, our case
had pigtail pus drainage performed for continuous pus
drainage, resulting in a final collection of 183.5 mL of
pus fluid in 11 days. All 5 cases had antibiotic therapy
for 4–6 weeks, longer than ordinarily needed by
healthy children.
The presence of multiple abscess lesions in these
5 cases is also quite different from the single abscess
lesion reported in non-ALL children with pyomyositis.
Hematogenous spread is a possible cause and it may be
necessary to drain the abscess lesions several times.
To date, 5 ALL children suffering from pyomyositis
during induction chemotherapy have been reported.
The pathogenesis is poorly understood. Previous
reports have described possible precipitating factors
such as neutropenia, immunosuppression secondary
to their disease and therapy, drug-induced muscle
injury potentially resulting from prednisolone
treatment, or muscle trauma from injected
L-asparaginase.10 However, there was no L-asparaginase
injection before our patient began suffering from
pyomyositis. More research is needed to determine
the pathogenesis.
In conclusion, local muscle pain, a symptom of
pyomyositis, might be misinterpreted as due to
vincristine neurotoxicity, until the symptoms get worse
or when fever occurs. It may prolong the course of
pyomyositis or result in severe complications.
Pyomyositis should be included in the standard
diagnostic procedure of children with ALL who present
with local pain during induction chemotherapy.
Effective standard treatment involves antibiotic
therapy, incision, and drainage. Antibiotic therapy
should initially cover S. aureus until the specific
organism is identified. With early recognition and
appropriate medical and surgical care, the treatment
course can be shortened and morbidity and mortality
can be avoided.
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